Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPPDA
说明： GluN2C/GluN2D-selective NMDA antagonist
化学名： (2S*,3R*)-1-(Phenanthren-2-carbonyl)piperazine-2,3-dicarboxylic acid
纯度： ≥98% (HPLC)
生物活性 for PPDA
PPDA is a subtype-selective NMDA receptor antagonist that preferentially binds to GluN2C/GluN2D (formally NR2C/NR2D) containing receptors (Ki values are 0.096, 0.125, 0.31 and 0.55 μM for GluN2C, GluN2D, GluN2B and GluN2A subunits respectively).
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
许可信息
Sold under license from UNeMed Corporation.
化合物库 for PPDA
PPDA is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for PPDA
| 分子量 | 378.38 |
| 公式 | C21H18N2O5 |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 684283-16-7 |
| PubChem ID | 90488770 |
| InChI Key | FAQARVDXAFZICA-QVUSPSOHSA-N |
| Smiles | O=C(C2=CC=C3C(C=CC4=C3C=CC=C4)=C2)N1[C@@H]([C@](O)=O)[C@@H]([C@](O)=O)NCC1.O=C(C6=CC=C7C(C=CC8=C7C=CC=C8)=C6)N5[C@H](C(O)=O)[C@H](C(O)=O)NCC5 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for PPDA
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| 2eq. NaOH | 18.92 | 50 | |
| DMSO | 37.84 | 100 |
制备储备液 for PPDA
以下数据基于产品分子量 378.38。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.64 mL | 13.21 mL | 26.43 mL |
| 5 mM | 0.53 mL | 2.64 mL | 5.29 mL |
| 10 mM | 0.26 mL | 1.32 mL | 2.64 mL |
| 50 mM | 0.05 mL | 0.26 mL | 0.53 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for PPDA
参考文献 for PPDA
参考文献是支持产品生物活性的出版物。
Feng et al (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid. Br.J.Pharmacol. 141 508 PMID: 14718249
Morley et al (2005) Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J.Med.Chem. 48 2627 PMID: 15801853
Kinarsky et al (2005) Identification of subunit- and antagonist-specific amino acid residues in the N-MthD.-aspartate receptor glutamate-binding pocket. J.Pharmacol.Exp.Ther. 313 1066 PMID: 15743930
If you know of a relevant reference for PPDA, please let us know.
按产品操作查看相关产品
关键词: PPDA, PPDA supplier, Subtype-selective, NR2C/NR2D, antagonists, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, cis-ppda, GluN2C, GluN2D, 2530, Tocris Bioscience
5 篇 PPDA 的引用文献
引用文献是使用了 Tocris 产品的出版物。 PPDA 的部分引用包括：
Mirante et al (2014) Distinct molecular components for thalamic- and cortical-dependent plasticity in the lateral amygdala. Autophagy 7 62 PMID: 25071439
Ferando and Mody (2013) Altered gamma oscillations during pregnancy through loss of δ subunit-containing GABA(A) receptors on parvalbumin interneurons. Front Neural Circuits 7 144 PMID: 24062647
Carlson et al (2012) Pharmacological evidence that D-aspartate activates a current distinct from ionotropic glutamate receptor currents in Aplysia californica. Brain Behav 2 391 PMID: 22950043
Carlson and Fieber (2012) Unique ionotropic receptors for D-aspartate are a target for serotonin-induced synaptic plasticity in Aplysia californica. Comp Biochem Physiol C Toxicol Pharmacol 155 151 PMID: 21497673
Pan et al (2016) Neuronal firing patterns outweigh circuitry oscillations in parkinsonian motor control. J Clin Invest 126 4516 PMID: 27797341
您是否知道使用了 Tocris PPDA 的优秀论文？ 请告知我们.
PPDA 的评论
目前没有该产品的评论。 Be the first to review PPDA and earn rewards!
Have you used PPDA?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.